Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023 07:50 ET
|
Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
May 02, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 02, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 23, 2022 12:01 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
North America Contract Research Organization Market Size to exceed $34.2 Bn by 2028, says Graphical Research
September 14, 2022 08:00 ET
|
Graphical Research
Pune, India, Sept. 14, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the North America contract research organization market is forecast to register...
Contract Research Organization (CRO) Market Trends 2022 | North America, Europe, & APAC Industry Forecasts 2028: Graphical Research
May 11, 2022 05:00 ET
|
Graphical Research
Pune, India, May 11, 2022 (GLOBE NEWSWIRE) -- The global contract research organization (CRO) market size is set to expand at substantial CAGR during the forecast period, owing to the rising...
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
February 14, 2022 16:15 ET
|
Vallon Pharmaceuticals Inc.
- Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with...
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 24, 2021 15:30 ET
|
Phathom Pharmaceuticals
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical ResearchPhase 1 population PK data abstract concludes the...
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
September 27, 2021 08:00 ET
|
Phathom Pharmaceuticals
Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACID®) 30 mg, a proton pump inhibitor (PPI) FLORHAM PARK,...